| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Gray Peter is a Director at JAZZ. Recent filings cover 0 purchases and 8 sales. Those positions are worth an estimated $2.2M at current prices.
Our model assigns Gray Peter a middling insider score of 63/100, based on 4 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +10.9%.
Gray Peter's largest disclosed position is in JAZZ as Director, worth about $2.2M. The recent filings there lean toward selling, a net 14,053 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2023 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,241 | $138.16 | $171,454.57 | -7.2% | -12.9% | -20.2% | |
| Aug 18, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sale+OE | 8,000 | $158.00 | $1,264,000.00 | -36.0% | -8.8% | -11.5% | |
| Aug 8, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,179 | $152.32 | $179,588.11 | -7.6% | -5.7% | -14.2% | |
| Aug 6, 2021 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,414 | $147.96 | $209,215.44 | -9.9% | -11.0% | +2.5% | |
| Aug 9, 2019 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 787 | $135.65 | $106,756.86 | -7.8% | - | - | |
| Aug 10, 2018 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 715 | $176.61 | $126,276.58 | -8.0% | - | - | |
| Aug 11, 2017 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 717 | $142.37 | $102,077.69 | -8.8% | - | - |